Company:  ATYR PHARMA INC (LIFE)
Form Type:  10-Q
Filing Date:  5/12/2020 
CIK:  0001339970 
Address:  3545 JOHN HOPKINS COURT, STE #250 
City, State, Zip:  SAN DIEGO, California 92121 
Telephone:  858-731-8389 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$3.71  
Change: 
-0.14 (-3.64%)  
Trade Time: 
Sep 25  
Market Cap: 
$36.89M
Trade LIFE now with

© 2020  
Description of Business
We are a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. We have concentrated our research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Built on more than a decade of foundational science on extracellular tRNA synthetase biology and its effect on immune responses, we have built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets, such as neuropilin-2 (NRP2). Our primary focus is on ATYR1923, a clinical stage product candidate which binds to the NRP2 receptor and is designed to down regulate immune engagement in interstitial lung diseases (ILDs).
Register and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      Item 1. Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures about ...
      Item 4. Controls and Procedures
    PART II. OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 3. Defaults Upon Senior Securities
      Item 4. Mine Safety Disclosure
      Item 5. Other Information
    Index to Exhibits
    SIGNATURES
  EXHIBIT 3.3
    RESTATED CERTIFICATE OF INCORPORATION
  EXHIBIT 31.1
    CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
  EXHIBIT 31.2
    CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED ...
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED ...